Buch, Englisch, 236 Seiten, Format (B × H): 155 mm x 235 mm, Gewicht: 388 g
Buch, Englisch, 236 Seiten, Format (B × H): 155 mm x 235 mm, Gewicht: 388 g
Reihe: Topics in Cardiovascular Disease
ISBN: 978-1-4615-9181-8
Verlag: Springer US
This monograph was developed from a collection of papers that were origi nally presented at a symposium entitled "Pathogenesis of Hypertension" held at the Henry Chauncy Conference Center, Princeton. New Jersey. These manuscripts were subsequently revised, updated, and reorganized in a manner suitable for this publication. The symposium was planned to stimu late interest among investigators and clinicians alike in the potential for a new class of drugs called converting enzyme inhibitors in clinical medicine. The meeting was sponsored by the Squibb Institute for Medical Research, whose pioneering biochemical and pharmaceutical research had led to the development of the first orally active converting enzyme inhibitor. It is hoped that this monograph will cohesively pull together the thesis that the identification, quantification, and containment of the renin factor in hypertension can be a powerful diagnostic and therapeutic strategy in clinical medicine. In addition, the sequence of studies presented in this manuscript will serve to demonstrate how basic biochemical and physio logical research produces fundamental and critical information on which subsequent major advances in clinical pharmacology and medicine can be based.
Zielgruppe
Research
Autoren/Hrsg.
Fachgebiete
Weitere Infos & Material
I Humoral and Physiological Mechanisms in Hypertension.- 1Blood Pressure Homeostasis.- 2Mechanisms of Hypertension Induced by Electrolyte-Active Steroids.- 3The Relationship of the Renal Medulla to the Hypertensive State.- 4The Influence of Various Neurological Defects on the Release of Renin in Normal Man.- 5Angiotensin as a Determinant of Renal Perfusion and Function.- 6Systemic Vascular Resistance: Regulation and Effect on Left Ventricular Function.- II Angiotensin-Converting Enzyme: Its Role and Development of Inhibitors.- 7Physiological, Biochemical, and Immunologic Aspects of Angiotensin-Converting Enzyme.- 8Design of New Antihypertensive Drugs: Potent and Specific Inhibitors of Angiotensin-Converting Enzyme.- 9Captopril (Capoten®; SQ 14,225) (D-3-Mercapto-2-methylpropanoyl-L-proline): A Novel Orally Active Inhibitor of Angiotensin-Converting Enzyme and Antihypertensive Agent.- 10Toxicologic and Drug Metabolic Studies of SQ 14,225 in Animals.- 11Captopril: An Oral Angiotensin-Converting Enzyme Inhibitor Active in Man.- III Clinical Use of Converting Enzyme Inhibitors.- 12The Renin System in High Blood Pressure, from Disbelief to Reality: Converting Enzyme Blockade for Analysis and Treatment.- 13Experiences with Blockade of the Renin System in Human Hypertension Using Converting Enzyme Inhibitor SQ 20,881 and Saralasin.- 14The Use of SQ 20,881 Converting Enzyme Inhibitor (Teprotide) for Diagnostic Purposes in Hypertension.- 15Clinical Experience with Blockade of the Renin-Angiotensin-Aldosterone System by an Oral Converting Enzyme Inhibitor (SQ 14,225, Captopril) in Hypertensive Patients.
